Periodontitis is one of the most common human inflammatory diseases, yet the mechanisms that drive immunopathology and could be therapeutically targeted are not well defined. Here, we demonstrate an expansion of resident memory T helper 17 (T H 17) cells in human periodontitis. Phenocopying humans, T H 17 cells expanded in murine experimental periodontitis through local proliferation. Unlike homeostatic oral T H 17 cells, which accumulate in a commensal-independent and interleukin-6 (IL-6)-dependent manner, periodontitis-associated expansion of T H 17 cells was dependent on the local dysbiotic microbiome and required both IL-6 and IL-23. T H 17 cells and associated neutrophil accumulation were necessary for inflammatory tissue destruction in experimental periodontitis. Genetic or pharmacological inhibition of T H 17 cell differentiation conferred protection from immunopathology. Studies in a unique patient population with a genetic defect in T H 17 cell differentiation established human relevance for our murine experimental studies. In the oral cavity, human T H 17 cell defects were associated with diminished periodontal inflammation and bone loss, despite increased prevalence of recurrent oral fungal infections. Our study highlights distinct functions of T H 17 cells in oral immunity and inflammation and paves the way to a new targeted therapeutic approach for the treatment of periodontitis.
INTRODUCTION
Periodontitis is one of the most prevalent human inflammatory diseases and poses a serious economic and public health burden (1) . In this condition, exaggerated inflammatory responses in the oral mucosal tissues surrounding the dentition (gingiva) lead to immunopathology and destruction of supporting bone (2) . To date, the pathogenic drivers of exaggerated destructive inflammation are incompletely understood, and treatment largely aims at reduction of microbial stimulation rather than at targeting of specific immune pathways through hostmodulation therapies (2) . In the lesions of human chronic periodontitis, expression of the cytokine interleukin-17 (IL-17) (3) (4) (5) (6) and an abundance of T helper 17 (T H 17) cells have been reported but not causally linked to periodontal disease pathogenesis (3, (5) (6) (7) . Here, we test the hypothesis that T H 17 cells are drivers of pathogenic mucosal inflammation in periodontitis.
In various mucosal surfaces, T H 17 cells are critical regulators of barrier immunity. Yet, amplification and dysregulation of IL-17-secreting cells in the setting of disease has been linked to immunopathology (8) (9) (10) . T H 17 cells have been implicated in the development of psoriasis in the skin and colitis at the lower gastrointestinal (GI) tract (8) (9) (10) . The physiologic immune protective role of T H 17 cells is particularly evident at the oral mucosal barrier. Defects in T H 17 cells and in IL-17 cytokine signaling underlie susceptibility to oral fungal infection (candidiasis) in both human and murine models (11) . Specifically, patients with primary immunodeficiencies affecting either T H 17 cell differentiation or function (12, 13) all have susceptibility to oral candidiasis. Although the homeostatic role of T H 17 cells at the oral mucosa is well delineated, the role of T H 17 cells in the development of oral immunopathology, particularly in humans, has not been conclusively defined.
Periodontitis provides an attractive setting to study T H 17-associated chronic inflammation in humans (14) . This disease is particularly common, and affected tissues are readily accessible for obtaining mucosal biopsy samples and corresponding microbiome samples directly from specific mucosal microenvironments, allowing for direct evaluation of the host-microbiome interplay at a specific site. Furthermore, T H 17 cells in the oral mucosa not only have a wellestablished role in oral antifungal immunity (11) but are also associated with local inflammatory lesions in periodontitis. Therefore, oral tissue is a unique setting in which to dissect distinct regulation and function of T H 17 cells in tissue immunity and inflammation.
Previous work in our laboratory has highlighted unique requirements for homeostatic development of T H 17 cells at the oral mucosa (15) . Unlike other barrier sites, such as the skin and lower GI tract, T H 17 cells may arise at the oral mucosa independently of commensal colonization. Ongoing damage through mastication is a unique tissuespecific cue for the development of homeostatic T H 17 cells in oral tissues in health (15) . However, the mechanisms implicated in the amplification and dysregulation of T H 17 cells in chronic periodontitis are poorly understood. We aimed to characterize the phenotypic and functional characteristics of human periodontitis-associated T H 17 cells and investigated T H 17 cell induction and functionality in periodontitis through complementary studies in experimental models and human systems.
Here, we document that expansion of T H 17 cells in periodontitis is mediated by the disease-associated microbiome and is dependent on both IL-6 and IL-23, revealing divergent regulation of oral T H 17 cells in health versus disease (15) . Through complementary human and animal experimentation, we demonstrate that T H 17 cells are required for periodontal tissue destruction and can be therapeutically targeted. Collectively, our use of concurrent and consistent evidence from both experimental and clinical models reveal microbially driven T H 17 cells as pathogenic drivers in periodontitis.
RESULTS

Inflammatory lesions in periodontitis are dominated by a T H 17 cell signature
In the oral disease periodontitis, mucosal tissues surrounding the dentition (gingiva) become heavily infiltrated by inflammatory cells with high representation of T cells (Fig. 1 , A to C) (6, 16) . Comparison of inflamed gingival tissues from periodontitis patients with healthy gingiva from volunteers revealed that, among known T H -associated factors, IL-17 had the highest expression in periodontitis (Fig. 1D) , suggesting a bias toward T H 17 cell differentiation in disease lesions (16, 17) . Ex vivo stimulation of cell preparations from healthy and diseased gingiva also revealed significantly increased numbers and proportion of CD45 + IL-17 + cells in periodontitis samples compared to healthy tissues (P < 0.05; Fig. 1 (Fig. 1G) . T H 17 cells were significantly increased in periodontitis lesions compared to health (P < 0.05; Fig. 1, H and I, and fig. S1B ) and, importantly, their proportion correlated with disease severity as reflected by tissue destruction-bone loss in millimeters (Fig. 1J) . T H 17 cells in periodontitis were almost exclusively memory cells (CD45RO + CD45RA − ; ~99%), predominantly tissue resident cells, primarily resident effector memory (rT EM ; ~60%), and secondarily resident central memory T cells (rT CM ; ~20%) ( Fig. 1, K and M) . After ex vivo stimulation, periodontitis-associated T H 17 cells coproduced cytokines linked to pathogenicity (10) such as granulocyte-macrophage colony-stimulating-factor (GM-CSF; ~30%) and interferon- (IFN-; ~15%), whereas a subset of T H 17 cells coproduced IL-22 (~15%) (Fig. 1, N and O) .
T H 17 cells selectively expand in experimental periodontitis
To mechanistically dissect the role of T H 17 cells in periodontal inflammation, we used an established murine model of experimental periodontitis, ligature-induced periodontitis (LIP). In LIP, atraumatic placement of a silk suture (ligature) around the second molar tooth leads to local accumulation of bacteria and gingival inflammation followed by destruction of tooth-supporting bone ( fig. S2 , A to D) (18) . Within the inflammatory lesions of experimental periodontitis, there was a profound increase in Il17a gene expression (30-to 80-fold increase over control) ( Fig. 2A) , whereas other T H -associated cytokines and inflammatory mediators were essentially unaltered ( fig. S2E) fig. S3 , A to C). Collectively, our data document preferential local expansion of T H 17 cells in experimental periodontitis.
Expansion of T H 17 cells in periodontitis is dependent on IL-6 and IL-23
We next examined cytokine requirements for accumulation of T H 17 cells during LIP. IL-6 has been shown to be required for homeostatic T H 17 cell accumulation in gingiva (15) . Il6-deficient mice had significantly reduced (almost undetectable) T H 17 cells in control and a significant reduction of T H 17 cell accumulation during LIP (both P < 0.05; Fig. 3, A and B) . IL-1 and IL-23 have also been linked to T H 17 differentiation and/or expansion in other settings (9) . IL-1 was dispensable for gingival T H 17 cell accumulation in LIP (Fig. 3, C and D) , whereas IL-23 was required (Fig. 3, E and F) . Il1r1-deficient mice had comparable T H 17 cell numbers with wild-type controls, whereas Il23a (p19)-deficient mice displayed a significant reduction in T H 17 cell accumulation during LIP (P < 0.05). Together, these data highlight divergent regulation of T H 17 cells in healthy and diseased gingiva (LIP), with IL-6 being the necessary stimulus for homeostatic accumulation of T H 17 cells, whereas both IL-6 and IL-23 (but not IL-1) are required for T H 17 cell expansion in disease.
Expansion of T H 17 cells in periodontitis is triggered by a dysbiotic microbiome
We next investigated the local microbiome as a trigger for T H 17 cells in periodontitis. We examined the local microbial communities present on the ligature after 2 hours of placement (control) and after 5 days of disease induction (LIP). In comparison to control, LIP featured local microbial communities with shifts in the relative abundance of commensal species and significant alterations in community composition and structure (Fig. 4 , A to C; P < 0.05). Therefore, LIP is associated with alterations to local microbial communities consistent with dysbiosis, which we hypothesized may stimulate local gingival T H 17 cell amplification in periodontitis. To assess the contribution of the microbiome to T H 17 cell accumulation, mice were placed on a broad-spectrum systemic antibiotic (ATB) cocktail (doripenem-vancomycin-neomycin) for 2 weeks and subsequently were subjected to LIP experiments in the presence of continuous ATB treatment. In the presence of the ATB cocktail, the numbers of CD45 + IL-17 + cells remained unchanged despite LIP (Fig. 4D) . Although ATB treatment significantly affected T H 17 cell proportions (P < 0.05; fig. S4A ) and cell numbers, it did not affect other IL-17 cellular sources (Fig. 4E) . T H 17 cell numbers were significantly lower during LIP in the ATB group (P < 0.05), whereas the numbers of TCR + IL-17 + and ILC IL-17 + cells were not affected (Fig. 4E ), suggesting that the microbiota specifically triggers T H 17 cell accumulation in the gingival mucosa. Reduction of T H 17 cell accumulation in the presence of ATBs correlated with nearly absent proliferation of T H 17 cells (Fig. 4F) . To assess the spectrum of bacteria that mediate T H 17 cell accumulation, animals were placed on different single-regimen ATBs during LIP. Treatment with the broadspectrum ATB doripenem (which targets Gram-positive, Gramnegative, and anaerobic bacteria) was effective in inhibiting T H 17 cell expansion (Fig. 4G ). Vancomycin and ampicillin, which typically target Gram-positive bacteria, did not affect T H 17 cells (Fig. 4G and fig.  S4B ). Neomycin and metronidazole both significantly inhibited T H 17 cell accumulation when used as single agents (P < 0.05; Fig. 4G ). Neomycin is considered effective against Gram-negative and some Gram-positive bacteria, and metronidazole targets mostly anaerobic bacteria. ATBs that inhibited T H 17 cells led to a concurrent significant inhibition of periodontal bone loss (P < 0.05), whereas vancomycin, which did not inhibit T H 17 cells, also failed to inhibit periodontal bone loss ( Fig. 4H ). These findings suggest a causative link among periodontitis-associated microbiota, T H 17 cell accumulation, and periodontal bone loss.
Next, we inquired whether T H 17 cell accumulation was dependent on an increase in bacterial biomass. We reasoned that if increased biomass was necessary for T H 17 accumulation, then ATBs that inhibit T H 17 cells would also lead to a decrease in bacterial biomass. Whereas combination ATBs and neomycin alone were effective in both reduction of microbial load and T H 17 cells, doripenem and metronidazole were efficient in inhibiting T H 17 cell accumulation without reduction of microbial biomass (Fig. 4I ). These data indicate that, rather than global reduction in biomass, specific alterations in microbial communities are likely to be responsible for microbial T H 17 triggering in periodontitis.
Last, the specific shifts in microbial communities that are linked to T H 17 cell induction were characterized. 16S ribosomal RNA (rRNA) gene-based sequencing of LIP-associated communities in the presence or absence of different ATB regimens revealed effects of each ATB on the oral microbiome ( fig. S4C ). Combination of broad spectrum ATBs and neomycin targeted all bacteria associated with LIP through significant reduction in bacterial biomass (P < 0.05; Fig. 4I and fig. S4C ). Unlike neomycin, doripenem and metronidazole (which also inhibit T H 17 cell accumulation) did not target major constituents of LIPassociated communities (cluster 1: Enterococcus sp., Lactobacillus sp., and Pseudomonas sp.; fig. S4C ). Doripenem and metronidazole did inhibit other LIP-associated bacteria (cluster 2: Porphyromonadaceae spp., Lachnospiraceae spp., Erysipelotrichaceae spp., among other taxa); however, these constituents were also targeted by vancomycin, which did not inhibit T H 17 cell accumulation ( fig. S4C ). Different ATB regimens also resulted in an increase in relative abundance of select species. Therefore, our analysis did not reveal single bacterial candidates that may stimulate T H 17 cell expansion but demonstrated unique shifts of bacterial depletion and overgrowth which occurred with each ATB regimen. These data suggest that changes in the balance of the community may underlie dysbiosis and pathogenicity. (Fig. 5A and fig.  S5A ). In contrast, other cellular sources of IL-17 (TCR cells and ILC) remained essentially intact at both steady state and after experimental periodontitis (Fig. 5, C to F 
Inhibition of T H 17 cell differentiation confers protection from inflammatory bone loss
Stat3
fl/fll mice may be attributed directly to the lack of T H 17 cells rather than to a compensatory increase in T regs (21) .
To confirm these results using an independent approach, we used mice with a specific deletion of the master regulator of T H (Fig. 6A and fig. S6, A to D) . Collectively, these data demonstrate that genetic inhibition of T H 17 cell differentiation blocks the overall expansion of CD45 + IL-17 + cells during experimental periodontitis and confers protection from periodontal inflammatory bone loss. Therefore, T H 17 cells are directly implicated as a major pathogenic cell subtype in this inflammatory disease, which supports focus on T H 17 cell-targeted therapeutic approaches.
Pharmacologic targeting of RORt reduces inflammatory bone loss and suggests an IL-17-and neutrophil-mediated immunopathology in periodontitis
Next, the effect of GSK805, a small-molecule inhibitor of RORt-mediated transcription, T H 17 cell development, and function (22) , was evaluated in experimental periodontitis. To this end, mice were subjected to LIP in the presence or absence of oral GSK805. GSK805-treated mice displayed significantly reduced disease severity (measured as bone loss; P < 0.05) compared to control vehicle-treated mice (Fig. 6B) . Consistent with previous reports in other systems (22) , GSK805 treatment These experiments additionally provided a platform to evaluate mechanisms by which RORt/T H 17 cell inhibition prevents period ontal bone loss. For this, RNA sequencing (RNA-seq) of gingival tissues to assess transcription was used in the presence or absence of RORt/T H 17 inhibition. RORt targeting inhibited IL-17A/F (Fig. 6, C and D, and fig. S8 ) and downstream targets, such as factors mediating granulopoiesis and neutrophil recruitment (Csf3, Cxcl1, Cxcl2, and Cxcl5; Fig. 6, C and D, first panel) . Proinflammatory genes (Il1, Il1, Il6, and Ptgs2) were also inhibited ( Fig. 6, C and D, second panel) , in line with a role of IL-17 as an amplifier of inflammatory responses. Expression of genes associated with myeloid cell activation (Cd14, Trem-1, and Cxcl3) was also reduced (Fig. 6D, third panel) . Last, expression of molecules linked to tissue destruction and bone loss (Mmp3, Mmp10, Pprss22, Osm, and Car9; Fig. 6D , fourth panel) was down-regulated. In summary, our transcriptome analysis after RORt/ T H 17-targeted treatment provided insight into differentially regulated genes and pathways, which collectively suggest inhibition of IL-17 signaling primarily affecting the function of neutrophils and other myeloid cells. Although neutrophils are suspected to mediate tissue destruction in periodontitis (23) , no direct cause-and-effect relationship has been reported thus far. We next investigated whether IL-17 and related neutrophil immunopathology is implicated in periodontal bone loss by blocking IL-17. In line with IL-17 playing a primary role in T H 17 cell-mediated immunopathology, antibody inhibition of IL-17 led to significant reduction of periodontal bone loss (P <0.05; Fig. 6E ). Reduction of neutrophil numbers ( fig. S8B ) by means of anti-Ly6G treatment also led to significant inhibition of period ontal bone loss (P < 0.05; Fig. 6F ). The involvement of neutrophils in periodontal tissue destruction is consistent with neutrophil accumulation in lesions of periodontitis in mice and humans ( fig. S8, C to E) . Collectively, our data suggest that T H 17 cell-derived IL-17 and neutrophils mediate pathology in periodontitis.
Humans with defects in T H 17 differentiation present with reduced periodontal inflammation and bone loss
If T H 17 cells are important in human periodontitis as our preclinical data suggests, then one would expect protection against periodontal inflammation and bone loss when T H 17 cells are reduced or inhibited. To evaluate the clinical consequences of T H 17 cell inhibition in humans, we studied patients with the Mendelian disorder autosomal dominant hyper-immunoglobulin E syndrome (AD-HIES), a unique real-life setting to decipher the pathophysiologic role of T H 17 cells in humans. AD-HIES patients bear an autosomal dominant, loss-of-function mutation in the STAT3 gene (12) , which leads to reduced STAT3 signaling and consequent defective differentiation of T H 17 cells (24) . These patients do not have circulating T H 17 cells, and their T cells display reduced in vitro (n = 9). Data combined from three separate experiments. All P values were determined by unpaired t test and graphs depict mean ± SEM. All P values are indicated in graphs.
differentiation into T H 17 cells (24). Among the described T H 17 cell human defects, AD-HIES is the most common, thereby allowing for evaluation of a fairly large Mendelian cohort rather than select patient cases.
Consistent with blunted T H 17 cell differentiation, AD-HIES patients exhibited significantly reduced numbers of T H 17 cells within gingival tissues as compared to age-and gender-matched healthy volunteers and periodontitis patients (P < 0.05; Fig. 7, A and B) . In line with the functional consequences of blunted tissue-T H 17 cell responses and previous reports (25), we documented a selective susceptibility to oral candidiasis in this population, with 85% reporting recurrent oral thrush (Fig. 7C) . Therefore, these patients constitute an appropriate cohort for investigating the consequences of local oral mucosal T H 17 cell deficiency in periodontal immunity and inflammation.
Our large cohort of adult AD-HIES patients (n = 35) with confirmed STAT3 mutations was clinically evaluated for presence and history of periodontal inflammation and tissue destruction. In stark contrast to their susceptibility to oral fungal infection, AD-HIES patients did not demonstrate susceptibility to periodontal disease. A detailed clinical evaluation revealed significantly reduced periodontal inflammation and attenuated bone loss (reduced clinical attachment loss; P < 0.05) in AD-HIES patients compared to age-or gender-matched healthy controls and periodontitis patients (Fig. 7, D and E). These findings suggest that blunted T H 17 cell responses confer protection from periodontal inflammatory disease in humans. Therefore, our clinical data from AD-HIES patients provide the human relevance of our murine mechanistic experiments and reinforce the distinct roles of oral T H 17 cells in immunoprotection and immunopathology.
DISCUSSION
At mucosal barrier sites, the local immune system is tasked with the delicate act of maintaining a dynamic balance between host and environmental stimuli (26) . Although much work in recent years has focused on the regulation of barrier immunity at the lower GI tract and skin, little is understood regarding the critical elements of oral barrier immunity. Yet, the oral mucosa is constantly exposed to a myriad of environmental stimuli (15) , including a rich and diverse commensal microbial community. It is the initial portal of encounter for microbes, food, and airborne antigens as they enter the GI tract, all in the context of mechanical stress (mastication) (27) . Hence, it is of great significance to understand how immunity is regulated at this critical barrier.
In our current work, we focused on the T H 17 cell subset, which is not only pivotal for oral antifungal immunity (11, 25) but also has been documented to expand in the oral inflammatory disease, periodontitis (6, 28, 29) . Our studies, using complementary human and murine datasets, demonstrate divergent regulation of oral T H 17 cells in health and disease and implicate T H 17 cells as drivers of disease pathogenesis and plausible therapeutic targets.
We investigated mechanisms by which T H 17 cells are triggered to expand in the setting of periodontitis and potentially participate in disease pathogenesis. In human lesions of periodontitis, we document an expansion of T H 17 cells that secrete cytokines associated with pathogenic activity (10, 30) and are predominantly resident memory T H 17 cells (31) . rT EM cells are thought to be retained in tissues to become terminally differentiated and to be capable of mounting rapid responses to site-specific cues (31) . These findings imply that T H 17 memory cells expand locally in response to tissue-specific cues and potentially acquire pathogenic functions. In this regard, experimental data in murine models of periodontitis points to a disease-associated All other P values determined by unpaired t test, and graphs depict mean ± SEM unless otherwise stated.
microbiome being a local stimulus for T H 17 cell expansion and related bone loss in periodontitis. These studies provide an opportunity to compare and contrast regulation of gingival T H 17 cells in health and disease. Our previous work had investigated the physiologic regulation of oral T H 17 cells in health. We found that T H 17 cells naturally accumulate in the oral mucosa with age (15) . This physiologic accumulation of T H 17 cells was dependent on ongoing mechanical stimulation, which occurs during mastication, and induces T H 17 cell accumulation in an IL-6-and commensal-independent manner (15). Our current work investigates mechanisms involved in further amplification of T H 17 cells observed in periodontitis. Amplification of T H 17 cells in periodontitis is dependent on microbial triggering. Furthermore, whereas homeostatic T H 17 cells are dependent solely on IL-6, disease-associated T H 17 cell expansion requires both IL-6 and IL-23. IL-23 is known to be required for pathogenic T H 17 cell development in other experimental disease settings (11) .
We further investigated microbial triggering of T H 17 cells in periodontitis. Microbial induction of T H 17 cells has been well documented at various other barrier sites, including the lower GI (32) and skin (33) . Barrier T H 17 cells have been documented to have specificity for local commensals in the GI tract (34 IL-17 + in periodontitis. We find that dysbiotic changes in microbial communities, rather than a mere increase in total microbial load, are necessary for induction of T H 17 cells that cause disease. Antibiotics that inhibited T H 17 cell accumulation did not necessarily reduce microbial load or target specific high-abundance bacterial species. Rather, the protective antibiotics appeared to mediate shifts in the balance of commensal bacteria within communities. However, treatment with protective antibiotics did not reveal specific bacteria that stimulate T H 17 cell accumulation but suggested that dysbiotic changes involving anaerobes mediate pathogenic inflammation. The human periodontal disease-associated microbiome is characterized by microbial overgrowth and dysbiotic shifts in bacterial communities, with an overgrowth of Gram-negative anaerobes (36, 37) . However, in human disease, it is not practical to dissect whether increased biomass, specific constituents, or global shifts in microbial communities are directly important for disease induction, because evaluation of microbial communities is performed after establishment of disease, not allowing for identification of disease-initiating factors. The present study has succeeded in uncoupling disease initiation from nonspecific biofilm accumulation and further supports dysbiotic changes as the trigger for T H 17 cell accumulation and downstream bone loss. In this regard, it should be noted that periodontitis is currently thought to be driven by dysbiosis of synergistic polymicrobial communities characterized by an imbalanced growth of a subset of commensal species (also known as pathobionts) rather than by a single or select few pathogens (14, (38) (39) (40) . Standardof-care treatment of periodontal disease currently aims at removal of the periodontitis-associated microbial commensal communities (37, 41, 42) by means of mechanical dental debridement with adjunct systemic antibiotics for severe disease (43) . Metronidazole, which effectively inhibited T H 17 cell accumulation, is an ATB of choice in human periodontitis, because it classically targets anaerobes. Although the link of commensal microbes to periodontal destructive inflammation is well documented clinically (42) , the mechanisms by which commensal bacteria induce pathogenic inflammation in periodontitis are poorly understood. Our work establishes T H 17 cells as the missing mechanistic link between microbial stimulation and induction of inflammatory immunopathology in periodontitis. Specific genetic targeting of T H 17 cells (by knocking out Stat3 or Rorc in  T cells) led to inhibition of T H 17 cell differentiation in gingival mucosal tissues, without interruption or augmentation of other cellular sources of IL-17. Inhibition of T H 17 differentiation led to significantly reduced bone loss (50 to 70%), suggesting that T H 17 cells constitute a major driver of periodontal immunopathology. Our genetic targeting of T H 17 cells without interrupting other sources of IL-17 could be important for maintenance of homeostatic immune protection as is the case in the lower GI tract, where total inhibition of IL-17 becomes detrimental for barrier integrity (44) . Similarly, in our pharmacological inhibition of RORt, we selected a small-molecule inhibitor (GSK805) that preferentially targets T H 17 cell differentiation (45) while sparing other sources of IL-17 (22) . Small-molecule inhibitors of RORt have been advocated and are currently being tested in T H 17 cell-dominated diseases (46) (47) (48) . These inhibitors may be ideally suited for localized diseases, such as periodontitis, where local treatment can avoid systemic effects on thymocyte and lymph node development (47, 49) .
Therapeutic inhibition of RORt/T H 17 cells in experimental periodontitis also afforded us the opportunity to investigate mechanisms whereby T H 17 cells mediate periodontal immunopathology. By performing RNA-seq transcriptome analysis of periodontitis lesions after 5 days of LIP in the presence of RORt or vehicle, we evaluated genes inhibited during RORt/T H 17 treatment. Zeroing in on specific gene regulation, we detected a signature consistent with inhibition of IL-17 and IL-17-dependent pathways. Although a dominant inhibition of IL-17-related genes was observed, we cannot completely rule out off-target effects of RORt inhibition. Top genes inhibited included IL-17-dependent neutrophil recruitment, granulopoiesis, macrophage activation, and overall activation of proinflammatory pathways (50) . Identification of inhibited genes also revealed an overall reduced activation of matrix and bone destruction. These findings suggest that the main mediator of T H 17 cellinduced immunopathology is IL-17. Inhibition of the cytokine IL-17 significantly inhibited periodontal bone loss. To investigate mechanisms by which IL-17 mediates periodontal immunopathology, we focused on neutrophils as candidate downstream drivers of immunopathology. Top genes inhibited during small-molecule T H 17 cell inhibition were related to neutrophil granulopoesis and neutrophil recruitment. Neutrophil accumulation is also known as a hallmark of human periodontitis and has been long speculated as a driver of pathology (23, 51, 52) . Our experimentation revealed that reduction of neutrophil accumulation protects from periodontal bone loss. Together, these data suggest a microbial T H 17 cell neutrophil axis as a driver for periodontitis immunopathology. Although it is well established that neutrophils secrete tissue-destructive proteases (53), further work is needed to dissect mechanisms by which neutrophils mediate downstream osteoclast activation and bone loss. In this respect, a recent study has shown a requirement for inflammationassociated receptor activator of nuclear factor κ ligand (RANKL) expression in osteoblasts for induction of periodontal bone loss (28) .
IL-17 has previously been shown to be a primary mediator of periodontal immunopathology in settings of altered background immunity such as immune deficiency (54, 55) , diabetes (56) , and aging (57) . We have identified IL-23/IL-17 dysregulation in periodontitis associated with the rare genetic disorder, leukocyte adhesion deficiency type 1 (LAD1), and have exploited that target by IL-23 blockade in humans (55) . Despite the commonality of T H 17 cell amplification in both endemic and genetic forms of periodontitis, T H 17 cell regulation and functionality appears to be distinct in genetic versus common forms of disease. In LAD1, defective neutrophil transmigration leads to tissue neutropenia, which underlies amplification of T H 17 cell responses. Furthermore, T H 17 cell-mediated bone destruction occurs in the absence of tissue neutrophils in LAD1. In contrast, in common periodontitis, neutrophil accumulation is a hallmark of disease and a driver of periodontal bone loss. Collectively, our previous and current work suggest distinct regulation and functionality of T H 17 cells in genetic and common forms of periodontitis, which nonetheless may respond to a common therapeutic target.
Our work further establishes human relevance by evaluating patient cohorts with known genetic defects leading to impaired T H 17 cell differentiation (AD-HIES) (24) . We document that AD-HIES patients have blunted T H 17 cell mucosal responses and susceptibility to recurrent oral fungal infection but reduced periodontal inflammation (bleeding on probing) and bone loss compared to healthy volunteers. These findings are consistent with a key role for T H 17 cells in oral inflammatory bone loss and provide a unique demonstration of the distinct roles of T H 17 cells within the same tissue and in the human setting.
A limitation of our current study is that the bulk of data implicating T H 17 cells in periodontitis pathogenicity comes from animal experimentation. Although patients with AD-HIES present with reduced periodontitis susceptibility, it is not possible to formally prove resistance to periodontitis in this setting. Future biologic treatment studies of T H 17 inhibition are necessary to conclusively implicate T H 17 cells in human periodontitis pathogenesis and to evaluate safety and efficacy of such T H 17-based treatment in humans. In this regard, our current study not only reveals critical insights into the regulation of T H 17 cells at the oral barrier but also provides mechanistic justification for T H 17 targeting in human periodontitis.
MATERIALS AND METHODS
Study design
This study evaluated mechanisms of T H 17 cell accumulation in the disease periodontitis and in experimental periodontitis and assessed preclinical T H 17 cell targeting. Oral clinical evaluation and biopsy sampling were performed in healthy volunteers, patients with periodontitis, and AD-HIES patients. Oral examinations included full mouth periodontal examination with a standardized instrument (periodontal probe Hu-Friedy UNC 15 probe). Gingival biopsies were obtained for histology and evaluation of T H 17 cells by flow cytometry. All subjects were enrolled in an Institutional Review Board-approved protocol (ClinicalTrials.gov #NCT01568697 and #NCT00404560) at the National Institutes of Health (NIH) Clinical Center, and all provided written informed consent. For inclusion in this study, AD-HIES patients were diagnosed on the basis of clinical phenotype and a positive STAT3 mutation. Healthy volunteers were systemically healthy on the basis of medical history and select laboratory testing. Periodontitis patients presented with more than four sites of moderate-severe bone loss and visible signs of inflammation (see the "Inclusion and exclusion criteria" section in supplementary materials and methods).
For experimental periodontitis studies in mice, LIP was performed as previously described (18) in different strains of mice in the presence or absence of ATB treatments, RORt inhibition, FTY720 treatment, or antibody treatments to block IL-17, Ly6G, or isotype controls. Bone loss was evaluated by morphometric analysis. Investigators were blinded to genotype and treatment during bone loss measurements. Group size for bone loss measurements (n = 5) was determined by power analysis calculations on the basis of previous pilot experiments for P < 0.05 and a power of 0.80. T H 17 cells within tissues were evaluated by flow cytometry. Murine oral microbiome was evaluated by 16S rRNA gene sequencing, and transcriptional responses in gingiva in the presence or absence of RORt inhibition were evaluated by RNA-seq and analysis. Experimental approaches are further detailed in the supplementary materials. Primary data are located in table S2.
Statistical analysis
Flow cytometry, real-time polymerase chain reaction, and bone loss measurement data were evaluated by Shapiro-Wilk normality test. Two-tailed unpaired t test or Mann-Whitney test was used when comparing two groups. When more than two groups were compared, ANOVA or Kruskal-Wallis with post hoc analysis was applied. P values < 0.05 were considered statistically significant. Data were analyzed using Prism 7 program (GraphPad Software). For RNA-seq analysis, gene expression was evaluated by three independent statistical methods (DESeq2, edgeR, and limma-voom). Differentially expressed genes (FDR < 0.05) were considered for further analyses on the basis of results from edgeR. For 16S rRNA gene-sequencing analysis, AMOVA was used to test for differences in community diversity and structure, as implemented in mothur (www.mothur.org).
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